Annual report pursuant to Section 13 and 15(d)

Revenue (Details)

v3.23.1
Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended 27 Months Ended
Jul. 01, 2021
Sep. 30, 2021
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2024
Disaggregation of Revenue [Line Items]            
Proceeds from upfront fees       $ 19,500    
Revenues       18,051 $ 5,398  
Proceeds from short-term debt       800 $ 400  
Discontinued Operations, Disposed of by Sale | Pediatric Portfolio            
Disaggregation of Revenue [Line Items]            
Proceeds from divestiture of businesses     $ 2,000      
Other long-term assets       1,800    
Other receivables       $ 1,000    
Discontinued Operations, Disposed of by Sale | Pediatric Portfolio | Scenario, Forecast            
Disaggregation of Revenue [Line Items]            
Proceeds from divestiture of businesses           $ 1,000
Major Customer Number One | Sales Revenue | Customer Concentration Risk            
Disaggregation of Revenue [Line Items]            
Concentration risk (as a percent)       68.00% 63.00%  
Major Customer Number Two | Sales Revenue | Customer Concentration Risk            
Disaggregation of Revenue [Line Items]            
Concentration risk (as a percent)       32.00% 21.00%  
Major Customer Number Three | Sales Revenue | Customer Concentration Risk            
Disaggregation of Revenue [Line Items]            
Concentration risk (as a percent)         16.00%  
AVTX-007            
Disaggregation of Revenue [Line Items]            
Proceeds from upfront fees       $ 14,500    
Product revenue, net            
Disaggregation of Revenue [Line Items]            
Revenues       3,364 $ 4,773  
Millipred | Teva Pharmaceutical Industries Ltd.            
Disaggregation of Revenue [Line Items]            
Percent of net profit for installment payments   50.00%        
Installment payments $ 500          
Royalty expense       1,900 $ 1,000  
AVTX-611            
Disaggregation of Revenue [Line Items]            
Revenues       $ 200